Assenagon Asset Management S.A. Reduces Holdings in Harrow, Inc. (NASDAQ:HROW)

Assenagon Asset Management S.A. trimmed its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 12,138 shares of the company's stock after selling 99,446 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Harrow were worth $323,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HROW. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its holdings in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Harrow during the 4th quarter valued at about $78,000. AlphaQuest LLC boosted its holdings in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after acquiring an additional 2,889 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of Harrow during the 4th quarter valued at about $214,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Trading Down 2.7%

NASDAQ HROW traded down $0.86 on Friday, hitting $30.66. 418,607 shares of the stock were exchanged, compared to its average volume of 499,162. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91. The stock has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $29.32. The firm has a market capitalization of $1.12 billion, a P/E ratio of -54.75 and a beta of 0.40. Harrow, Inc. has a 52-week low of $19.97 and a 52-week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. Research analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HROW. BTIG Research started coverage on shares of Harrow in a report on Thursday, June 12th. They set a "buy" rating and a $62.00 price target on the stock. William Blair assumed coverage on shares of Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating on the stock. B. Riley reduced their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, HC Wainwright lifted their price objective on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $61.40.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.